Inozyme Pharma, Inc.
INZY · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $26 | $21 | $25 | $15 |
| Short-Term Investments | $59 | $92 | $107 | $129 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $7 | $9 | $8 |
| Total Curr. Assets | $94 | $121 | $141 | $153 |
| Property Plant & Equip (Net) | $1 | $1 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $0 |
| Total NC Assets | $2 | $3 | $2 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $95 | $123 | $143 | $156 |
| Liabilities | – | – | – | – |
| Payables | $4 | $3 | $2 | $4 |
| Short-Term Debt | $26 | $15 | $6 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $13 | $16 | $11 | $10 |
| Total Curr. Liab. | $43 | $34 | $18 | $16 |
| LT Debt | $21 | $31 | $42 | $46 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $21 | $31 | $42 | $46 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $1 | $1 |
| Total Liabilities | $63 | $65 | $61 | $61 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$416 | -$388 | -$361 | -$336 |
| AOCI | -$0 | $0 | $0 | -$0 |
| Other Equity | $448 | $446 | $443 | $431 |
| Total Equity | $32 | $58 | $83 | $94 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $95 | $123 | $143 | $156 |
| Net Debt | $21 | $26 | $23 | $32 |